Type 2 diabetes. Non-insulin dependent type2 diabetes
Conditions
Interventions
Intervention 1: The intervention group received daily 500mg capsule quercetin for 10 weeks. Intervention 2: control group received 500mg placebo(lactose) daily for 10 weeks.
Treatment - Other
Placebo
The intervention group received daily 500mg capsule quercetin for 10 weeks
control group received 500mg placebo(lactose) daily for 10 weeks
Sponsors
Research Deputy of Isfahan University of Medical Sciences field
Eligibility
Sex/Gender
Female
Age
35 Years to 55 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria 1. Willingness to participate in the study 2. Type 2 diabetes diagnosed by a physician 3. Having a history of diabetes at least 3 years 4. Age between 35-55 years 5. Not smoking and addiction 6. Lack of severe heart disease, stroke, liver disease, renal, gastrointestinal, thyroid, parathyroid, rheumatoid arthritis and infectious disease 7. Lack of insulin 8. Lack of antioxidant supplements in the previous month 9. Lack of pregnancy and lactation Exclusion criteria 1. Need to change the dose and type of drug from the baseline to the end 2. Occurring in pregnancy 3. Less than 70% adherence 4. Unwillingness to continue reading 5. Staying beyond the fixed type and dose of drugs during the intervention. 6. There are diseases that require special treatment
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Systolic blood pressure. Timepoint: befor start and end of study. Method of measurement: Mercury Barometer - mmHg.;Total Cholesterol. Timepoint: befor start and end of study. Method of measurement: Enzymatically-mg/dl.;HDL-c. Timepoint: befor start and end of study. Method of measurement: Enzymatically-mg/dl.;LDL-c. Timepoint: befor start and end of study. Method of measurement: Enzymatically-mg/dl.;TG. Timepoint: befor start and end of study. Method of measurement: Enzymatically-mg/dl.;FBS. Timepoint: befor start and end of study. Method of measurement: Enzymatically-mg/dl.;HbA1c. Timepoint: befor start and end of study. Method of measurement: Enzymatically-mg/dl.;MDA. Timepoint: befor start and end of study. Method of measurement: ELISA-ng/ml.;Total antioxidant capacity. Timepoint: befor start and end of study. Method of measurement: Chemical colorimetric-mmol/L.;TNF-a. Timepoint: befor start and end of study. Method of measurement: ELISA-pg/ml.;Hs-CRP. Timepoint: befor start and end of study. Method of measurement: ELISA-mg/L.;IL-6. Timepoint: befor start and end of study. Method of measurement: ELISA-pg/ml.;Diastolic blood pressure. Timepoint: befor start and end of study. Method of measurement: Mercury Barometer - mmHg. | — |
Secondary
| Measure | Time frame |
|---|---|
| Physical Activity. Timepoint: before start and end of sudy. Method of measurement: IPAQ Questionnaire-Met.minutes/week.;Weight. Timepoint: before start and end of sudy. Method of measurement: Weight gauge-Kg.;Food intake. Timepoint: First, the fifth week, the tenth week. Method of measurement: Inventory Software N4.;The waist to hip circumference. Timepoint: before start and end of sudy. Method of measurement: Tape-Centimeter. | — |
Countries
Iran (Islamic Republic of)
Outcome results
None listed